FDA Clears Allogene’s IND for CAR T Therapy in Autoimmune Diseases

Allogene Therapeutics, Inc. ALLO announced that the FDA has cleared its investigational new drug (IND) application to begin clinical studies on its investigational CRISPR-based allogenic CAR-T therapy, ALLO-329, for the treatment of various autoimmune diseases. The phase I RESOLUTION basket study will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic lupus erythematosus, including lupus nephritis, idiopathic…